Bone complications: an increasing risk in patients with prostate cancer
Journal of Supportive Oncology 5(2): 88-89
2007
ISSN/ISBN: 1544-6794 PMID: 17348369 Document Number: 613392
Document emailed within 1 workday
Related Documents
Murray, N.P.; Aedo, S.óc.; Fuentealba, C.; Reyes, E.; Minzer, S.; Salazar, A.íb. 2019: Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer Archivos Espanoles de Urologia 72(5): 471-482Zhu, X-Dong.; Zheng, A.; Wang, Z-Qian.; Shao, Q. 2018: Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population Zhonghua Nan Ke Xue 24(2): 142-146
Zissimopoulos, A.; Bantis, A.; Stellos, K.; Petrakis, G.; Matthaios, D. 2008: Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients Journal of BUON: Official Journal of the Balkan Union of Oncology 13(1): 69-74
Zissimopoulos, A.; Stellos, K.; Matthaios, D.; Petrakis, G.; Parmenopoulou, V.; Babatsikou, F.; Matthaiou, E.; Theodosiadou, E.; Hountis, P.; Koutis, C. 2009: Type i collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy Journal of Buon: Official Journal of the Balkan Union of Oncology 14(3): 463-472
Dodds, P.R.; Boucher, J.D.; Shield, D.E.; Bernie, J.E.; Batter, S.J.; Serels, S.R.; Dodds, J.H. 2011: Are complications of transrectal ultrasound-guided biopsies of the prostate gland increasing? Connecticut Medicine 75(8): 453-457
Incorvaia, L.; Badalamenti, G.; Rini, G.; Arcara, C.; Fricano, S.; Sferrazza, C.; Di Trapani, D.; Gebbia, N.; Leto, G. 2007: MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone Anticancer Research 27(3b): 1519-1525
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Jaukovic, L.; Adjinovic, B.; Cerovic, S.; Joksimovic, M.; Soldatovic, Z. 2011: Is bone scintigraphy necessary in initial staging of prostate cancer patients? Hellenic Journal of Nuclear Medicine 14(2): 126-130
Lin, K.; Szabo, Z.; Chin, B.B.; Civelek, A.C. 1999: The value of a baseline bone scan in patients with newly diagnosed prostate cancer Clinical Nuclear Medicine 24(8): 579-582
Sapi, Z.; Bodo, M.; Vadasz, G.; Henson, D.E.; Haas, G.P. 1994: The increasing incidence of prostate cancer in Hungary In Vivo 8(3): 433-435
Leewansangtong, S.; Soontrapa, S. 2003: The pattern of prostate-specific antigen responses following hormonal therapy in Thai men with bone metastatic prostate cancer Journal of the Medical Association of Thailand 86(9): 809-815
Maroni, P.D. 2015: Is radical prostatectomy appropriate for very-high-risk prostate cancer patients? Yes Oncology 29(5): 348; 388
Boyle, J.M.; Lee, W.R. 2015: Is radical prostatectomy appropriate for very-high-risk prostate cancer patients? no Oncology 29(5): 349; 389
Ziaran, S.; Goncalves, F.M.; Wendl, J.; Trebaticky, B.; Breza, J.S. 2009: Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy Bratislavske Lekarske Listy 110(9): 559-562
Hori, J.; Wada, N.; Tamaki, G.; Azumi, M.; Kita, M.; Iwata, T.; Matsumoto, S.; Kakizaki, H. 2016: Combination of GnRH Antagonist Degarelix and Antiandrogen Is Effective in PSA Reduction and Bone Management in Patients with Prostate Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(6): 727-731
Agarwal, M.M.; Mandal, A.K.; Khandelwal, N.; Singh, S.K. 2007: Need for measurement of bone mineral density in patients of prostate cancer before and after orchidectomy: role of quantitative computer tomography Journal of the Association of Physicians of India 55: 486-490
Kobayashi, Y.; Tokue, A. 1998: Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients Nihon Rinsho. Japanese Journal of Clinical Medicine 56(8): 2072-2076
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Demers, R.Y.; Swanson, G.M.; Weiss, L.K.; Kau, T.Y. 1994: Increasing incidence of cancer of the prostate. The experience of black and white men in the Detroit metropolitan area Archives of Internal Medicine 154(11): 1211-1216
2015: (P063) Can Some High-Risk Prostate Cancer Patients Be Treated With a Shorter Course of Androgen Deprivation Therapy (ADT)? Oncology 29(4 Suppl. 1)